What Medical Demand Actually Means for the Gold Price

In 2025, roughly 322.8 tonnes of gold went into every technology and industrial use combined, dentistry, electronics, diagnostics, and medical devices all included. Investment demand that same year absorbed 2,175 tonnes on its own.

Gold’s role in medicine is centuries old, technically irreplaceable in several critical applications, and expanding into new directions such as rapid diagnostics and nanoparticle oncology. Yet the entire healthcare complex barely registers in the demand calculus that actually moves the metal’s price.

Investors who hold gold positions tend to meet the medical angle as a bullish talking point, and they deserve a rigorous account of what it genuinely means. This piece gives you a complete demand-side map, so you can evaluate any future headline about gold’s medical applications with the correct analytical lens rather than a misleading one.

Why gold works in the body when almost nothing else does

The word “irreplaceable” gets used loosely. In gold’s case, it earns its weight through four measurable physical properties that alternative materials struggle to replicate all at once.

Start with chemical inertness. As a noble metal, gold resists oxidation and corrosion inside the chloride-rich, protein-laden environment of the human body. That same stability, the property keeping a dental crown intact for decades in a mouth full of acid and saliva, is precisely the property that underpins gold’s durability as a monetary asset. The metal that does not corrode in your mouth is the metal that does not corrode in a vault.

The remaining three properties extend that reliability into more specialised roles.

• Optical properties (surface plasmon resonance): Gold nanoparticles produce an intense red or purple colour, the visible line you see on a lateral-flow diagnostic strip.
• Surface chemistry (thiol-gold bonds): Gold surfaces can be functionalised via ordered thiol-gold bonds, enabling an inert-core, active-shell design that carries cytotoxic payloads without uncontrolled degradation.
• Radiopacity: Gold’s high atomic number makes it clearly visible on X-ray and CT imaging, without the mechanical complications of bulkier markers.

Here is what this tells you as an investor. In high-performance healthcare settings, gold substitution is not a cost question. It is an engineering constraint. That distinction matters if you treat medical demand as free from substitution risk, because it separates the applications where gold is genuinely locked in from the ones where cheaper alternatives are already creeping through the door.

From 2,600-year-old dental bands to COVID test strips: gold’s medical range in practice

Etruscan dentists were fitting patients with gold dental bands around 630 BCE. The archaeological record of gold in the mouth stretches back roughly 2,600 years, which makes it one of the longest continuous uses of any material in medicine.

The modern era began in the late 19th century, when cast gold fillings and crowns entered dentistry properly. Pure gold is too soft to chew with, so clinicians alloy it with metals like palladium or copper to produce mixtures containing 60% to 78% gold. A correctly installed gold crown can remain functional for 15 to 30 years, degrading at roughly the same rate as the natural enamel beside it, which is gentler on opposing teeth than harder ceramics.

Modern applications: diagnostics, radiotherapy, and the oncology frontier

The mass-market modern use is diagnostics. Manufacturers bind antibodies to gold nanoparticles and calibrate them to detect a specific protein, a pregnancy hormone or a COVID-19 antigen. When a fluid sample reaches the coated zone, the nanoparticles cluster and produce a visible line through plasmon resonance. The pandemic cemented colloidal-gold strips as the consumer diagnostic standard.

A single rapid lateral-flow test strip uses only nanograms of gold.

Radiotherapy came earlier. Physicians at Baylor College of Medicine began implanting radioactive Au-198 seeds into prostate tumours in 1965, delivering localised radiation while sparing surrounding tissue. Thin, non-radioactive gold fiducial markers do a quieter job, letting surgeons confirm stent and implant positions under X-ray.

Then there is the oncology frontier, and here the picture demands honesty. Auranofin, an oral gold compound approved for rheumatoid arthritis in the 1980s, inhibits an enzyme called thioredoxin reductase that many aggressive cancer cells rely on. Laboratory studies show activity against ovarian, lung, and pancreatic cancer cells.

Laboratory activity is not clinical success. A Mayo Clinic Phase II trial (NCT03456700) tested auranofin with sirolimus in ovarian cancer and was terminated after 22 patients enrolled. There were no meaningful tumour responses, median progression-free survival was 2.1 months, and the registry status was formally updated to terminated in 2025.

The terminated trial is the single most important data point in this section for you. It signals that the oncology narrative around auranofin remains speculative. The global gold nanoparticles market may be growing at a projected 11.4% to 11.8% CAGR to 2034, but any bullish read on gold demand from cancer drug pipelines is, on current evidence, premature.

What the numbers actually say about medical gold and the price it does not move

Set the applications aside and look at the tonnage. Total worldwide gold demand hit a record 5,002.3 tonnes in 2025.

Investment demand accounted for 2,175 tonnes of that, itself a record, including 801 tonnes of ETF inflows. Central banks took 863 tonnes. All technology and industrial demand combined, the category holding electronics, dentistry, and every medical use, came to 322.8 tonnes, essentially flat year-on-year.

Now narrow to medicine specifically. Global dentistry consumed 8.2 tonnes in 2025, down 7% from 8.9 tonnes in 2024.

Medical and industrial gold consumption combined represents approximately 6% of total annual demand.

That 8.2 tonne dentistry figure sitting beside 2,175 tonnes of investment demand is the clearest single illustration of the point. A breakthrough medical application would need to be orders of magnitude larger than anything currently plausible to shift gold’s price structure.

The high-growth diagnostic market does not change this. Its CAGR describes value growth in dollars, not tonnage growth in metal, because each test strip uses nanograms. Billions of tests collectively amount to tens of tonnes at most.

What actually moves the price is monetary: real yields, currency strength (particularly the direction of the US dollar), and confidence in fiat monetary systems. When you see a bullish medical-gold narrative, check whether it conflates a growing market in dollar terms with a growing market in physical tonnage. The two are not the same, and only one is relevant to price.

Where the medical case for gold does and does not hold for investors

The evidence sorts cleanly into two categories once you know what to look for.

The first category is mature, stable, price-floor demand: dentistry, lateral-flow diagnostics, brachytherapy, and fiducial markers. These contribute a consistent physical tonnage base. They will not surprise to the upside.

The second is exploratory and tonnage-negligible: auranofin oncology and nanoparticle drug delivery. These generate headlines and occasional excitement, but represent no credible near-term demand catalyst.

Substitution risk deserves honest treatment too, because it is not theoretical.

• Gold-coated coronary stents were tested in cardiology trials in the late 1990s and early 2000s. Studies reported higher restenosis rates and adverse events, likely from micro-galvanic corrosion, and major manufacturers abandoned the technology in favour of cobalt-chromium and platinum-chromium alloys.
• Injectable chrysotherapy for arthritis declined sharply due to side effects including nephrotoxicity and bone-marrow suppression, with safer biologics taking over.
• Lower-performance diagnostics already substitute coloured latex, carbon, and fluorescent or magnetic nanoparticles where cost dominates.
• Nanoparticle biodistribution remains under study, with small gold particles accumulating in the liver and spleen and long-term immune effects still requiring characterisation.

These substitution cases are not bearish signals for gold overall. They are the calibration mechanism that shows you which applications have genuine lock-in and which are cost-sensitive and carry quiet substitution exposure.

The investor framework: price floor versus price catalyst

Here is the model to keep. Stable medical demand is a floor beneath physical use, not a driver of price. Gold’s physical uniqueness locks it into high-performance applications, but high-performance applications are not high-volume applications.

What you should monitor instead is monetary: real yield trajectories, central bank reserve accumulation, ETF flows, and fiat confidence indicators. These are the variables that will determine gold’s price over the next cycle.

Investor framework: The medical indispensability of gold supports a demand floor, not a price catalyst.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions. Past performance does not guarantee future results, and financial projections are subject to market conditions and various risk factors.

Gold’s medical footprint, correctly sized

The finding holds without softening. Gold’s medical indispensability is real, its tonnage contribution is small, and its pricing influence is marginal against monetary demand.

The fascination is real too. A metal fitted by Etruscan dentists around 630 BCE is now being engineered at nanogram scale to target cancer cells. That continuity of usefulness across 2,600 years says something meaningful about the material, and it is worth appreciating on its own terms.

But context sets the frame. Against 5,002.3 tonnes of total 2025 demand, the 322.8 tonnes of technology and industrial use is the ceiling for the sector’s contribution, and the record 2,175 tonnes of investment demand is the counterweight that actually sets the price.

The variables that will move gold’s price in the next cycle are monetary, not medical.

For anyone holding or evaluating gold exposure, the medical story is genuinely interesting context. It belongs in the background of the investment thesis, not the foreground. Keep your analytical attention on real yields, reserve policy, and flow sentiment, and let the test-strip volumes stay where they belong.